ArticleNPJ biofilms and microbiomes2026
Genetically engineered probiotic E. coli Nissle 1917 enhances protection against Salmonella via increased adhesion and systemic T-cell responses.
Article in NPJ biofilms and microbiomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The rise in antimicrobial resistance underscores the need for innovative strategies to combat gastrointestinal infections. Probiotics such as Escherichia coli Nissle 1917 (EcN) offer promising options, but the molecular mechanisms underlying their protective effects remain unclear. We introduce a G66R point mutation in FimH, creating a high-binding EcN variant that more effectively prevents Salmonella Typhimurium attachment and induces a distinct host transcriptional profile, shifting toward adaptive rather than innate inflammatory signaling. In vivo, EcN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.